96 related articles for article (PubMed ID: 24489105)
21. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
22. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
23. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.
Somasundaram R; Swoboda R; Caputo L; Otvos L; Weber B; Volpe P; van Belle P; Hotz S; Elder DE; Marincola FM; Schuchter L; Guerry D; Czerniecki BJ; Herlyn D
Cancer Res; 2006 Mar; 66(6):3287-93. PubMed ID: 16540682
[TBL] [Abstract][Full Text] [Related]
24. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
25. BRAF inhibitors and melanoma.
Flaherty KT
Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
[TBL] [Abstract][Full Text] [Related]
26. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
27. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
[TBL] [Abstract][Full Text] [Related]
28. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression.
Long GV; Wilmott JS; Haydu LE; Tembe V; Sharma R; Rizos H; Thompson JF; Howle J; Scolyer RA; Kefford RF
Pigment Cell Melanoma Res; 2013 Jul; 26(4):499-508. PubMed ID: 23557327
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the treatment-naive immune microenvironment in melanoma with
Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
[TBL] [Abstract][Full Text] [Related]
30. The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer.
Väyrynen JP; Kantola T; Väyrynen SA; Klintrup K; Bloigu R; Karhu T; Mäkelä J; Herzig KH; Karttunen TJ; Tuomisto A; Mäkinen MJ
Int J Cancer; 2016 Jul; 139(1):112-21. PubMed ID: 26874795
[TBL] [Abstract][Full Text] [Related]
31. Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8
Harbers FN; Thier B; Stupia S; Zhu S; Schwamborn M; Peller V; Chauvistré H; Crivello P; Fleischhauer K; Roesch A; Sucker A; Schadendorf D; Chen Y; Paschen A; Zhao F
J Invest Dermatol; 2021 Oct; 141(10):2480-2489. PubMed ID: 33798535
[TBL] [Abstract][Full Text] [Related]
32. B-Raf specific antibody responses in melanoma patients.
Fensterle J; Becker JC; Potapenko T; Heimbach V; Vetter CS; Bröcker EB; Rapp UR
BMC Cancer; 2004 Sep; 4():62. PubMed ID: 15361259
[TBL] [Abstract][Full Text] [Related]
33. Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis.
Wang X; Montoyo-Pujol YG; Bermudez S; Corpas G; Martin A; Almazan F; Cabrera T; López-Nevot MA
J Oncol; 2021; 2021():6610769. PubMed ID: 33574842
[TBL] [Abstract][Full Text] [Related]
34. Cytokine and Chemokine Receptor Patterns of Human Malignant Melanoma Cell Lines.
Koroknai V; Szász I; Jámbor K; Balázs M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269787
[TBL] [Abstract][Full Text] [Related]
35. Rehabilitation for oncogene addiction: role of immunity in cellular sobriety.
Bajor DL; Vonderheide RH
Clin Cancer Res; 2012 Mar; 18(5):1192-4. PubMed ID: 22266272
[TBL] [Abstract][Full Text] [Related]
36. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
Audrito V; Managò A; Zamporlini F; Rulli E; Gaudino F; Madonna G; D'Atri S; Antonini Cappellini GC; Ascierto PA; Massi D; Raffaelli N; Mandalà M; Deaglio S
Oncotarget; 2018 Apr; 9(27):18997-19005. PubMed ID: 29721178
[TBL] [Abstract][Full Text] [Related]
37. Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI; Wang Y; Pierce RH; Campbell JS; Yushak M; Milhem M; Ross M; Niland K; Arbeit RD; Parasuraman S; Bickley K; Yeung CC; Aicher LD; Smythe KS; Gan L
Cancer Res Commun; 2022 Aug; 2(8):904-913. PubMed ID: 36923305
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness.
Mocellin S; Ohnmacht GA; Wang E; Marincola FM
Int J Cancer; 2001 Jul; 93(2):236-42. PubMed ID: 11410872
[TBL] [Abstract][Full Text] [Related]
39. p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration.
Pandya P; Kublo L; Stewart-Ornstein J
Cells; 2022 Jan; 11(3):. PubMed ID: 35159215
[TBL] [Abstract][Full Text] [Related]
40. BRAF Inhibition: Bridge or Boost to T-cell Therapy?
Goff SL; Rosenberg SA
Clin Cancer Res; 2019 May; 25(9):2682-2684. PubMed ID: 30824585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
